Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“The recent FDA approval of oral decitabine/cedazuridine + venetoclax in AML may have implications extending beyond hematologic malignancies.
A recent case report described a durable near-complete response lasting >15 months with venetoclax + decitabine in heavily pretreated metastatic IDH2-mutant cholangiocarcinoma.
Interesting biological overlap:
- IDH2 mutations may create BCL-2 dependence
- D-2HG–driven hypermethylation may increase sensitivity to hypomethylating agents
- Potential synthetic lethality with BCL-2 inhibition
This is far from tumor-agnostic evidence.
But it raises an important translational oncology question:
Could some molecular vulnerabilities — such as IDH2-driven metabolic dependencies — eventually allow hematologic regimens to be adapted to selected solid tumors?”
Title: Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory IDH2-Mutant Cholangiocarcinoma
Authors: Eylül Özgü, Ünal Metin Tokat, Ashkan Adibi, Şevval Nur Bilgiç, Esranur Aydın, Onur Tutar and Mutlu Demiray
Other articles featuring Ahmet Dirican on OncoDaily.
